MBX

Mbx Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000

$55.87Close $2.5BMarket cap $20.61 – $70.7052-week range Nov 5, 2026Next report

Highlights

Strengths

Leading the market RS 95 · stronger than 95% of stocks over 12 months

Cautions

Trend not confirmed 7 of 8 conditions · under the 50-day
Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 6, 2026

Off 12-month high 21%

1wk 15.2% price change

1mo 4.7% price change

12-month return 156% market up 11% · its own up 175%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 6.8× price / book

Earnings yield 4.0% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 28% return on equity

Free cash margin — -$81.9M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 6.1% $3.42 a day · 2×ATR $49.03

RS 95 / 99 vs the universe

Trend 7 / 8 under the 50-day

Relative volume 1.3× vs 50-day average

Up/down volume 0.89 50 sessions

Implied move — no option chain · report Nov 5, 2026

Trend template · 7 of 8

Price above the 50-day average: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 34.4% over the year, from 33m to 45m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Aug 6, 2026

Results reaction Aug 6, 20260% vs market2 sessions after results

Financials

3 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$87.0M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$81.9M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 44.93m +3474.0% since FY2023

	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$35.3M	-$68.2M	-$98.1M
Net income	-$32.6M	-$61.9M	-$87.0M
Earnings per share	-$31.96	-$5.82	-$2.38
Free cash flow	-$32.1M	-$55.6M	-$81.9M
Cash	$30.5M	$49.4M	$75.3M
Shareholders' equity	-$72.5M	$257.4M	$369.2M
Shares outstanding	1.26m	33.42m	44.93m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 6, 2026	Quarterly ↗	Jun 30, 2026	37d
May 7, 2026	Quarterly ↗	Mar 31, 2026	37d
Mar 12, 2026	Annual ↗	Dec 31, 2025	71d
Nov 6, 2025	Quarterly ↗	Sep 30, 2025	37d
Aug 7, 2025	Quarterly ↗	Jun 30, 2025	38d
May 12, 2025	Quarterly ↗	Mar 31, 2025	42d
Mar 17, 2025	Annual ↗	Dec 31, 2024	76d
Nov 7, 2024	Quarterly ↗	Sep 30, 2024	38d

Current reports

Filed	Disclosed
Oct 22, 2026	Director or officer change ↗
Aug 27, 2026	Regulation FD · Other events ↗
Aug 6, 2026	Results · Regulation FD · Other events ↗
Jul 13, 2026	Director or officer change ↗
Jun 12, 2026	Regulation FD · Other events ↗
Jun 5, 2026	Director or officer change · Shareholder vote ↗
May 11, 2026	Regulation FD · Other events ↗
May 7, 2026	Results ↗
Mar 12, 2026	Results ↗
Mar 9, 2026	Regulation FD · Other events ↗
Feb 27, 2026	Material agreement · Director or officer change ↗
Feb 5, 2026	Other events ↗